BCAS2 Polyclonal Antibody - BT-AP00852

BCAS2 Polyclonal Antibody

Sizes: 20μL, 50μL, 100μL

Catalogue Numbers: BT-AP00852-20, BT-AP00852-50, BT-AP00852-100

Citations, Manuals and MSDS Available upon request.

Background: BCAS2 was identified through differential display analysis as an mRNA species that was overexpressed in MCF7 and BT-20 breast cancer cell lines. The chromosomal region containing this gene, 1p13.3021, is amplified in these cells lines. BCAS2 is a transcriptional cofactor that enhances estrogen receptor-mediated gene expression, and directly interacts with the tumor suppressor p53 to reduce p53 transcriptional activity by reducing p53 protein level in the absence of DNA damage. Deprivation of BCAS2 through RNA inhibition induces apoptosis in p53-wild type cells, but causes G2-M arrest in p53-null or –mutant cells; this effect was reversed with the expression of ectopic BCAS2. BCAS2 may thus be potentially useful as a therapeutic target in the treatment of cancer.

Research Areas: Tags and Cell Markers

Target Protein: BCAS2

Applications: WB, ELISA

Reactivity: Human, Mouse, Rat, Monkey

Clonality: Polyclonal

Host: Rabbit

Isotype: IgG

Full Product Name: BCAS2 Antibody

Immunogen: The antiserum was produced against synthesized peptide derived from human AMPK alpha around the phosphorylation site of Thr172. AA range:140-189

Storage: -20°C for 1 year

Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Formulation: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Concentration: 1 mg/ml

Molecular Weight (Da): 26131

UniProt Accession: Human: O75934; Mouse: Q9D287

Synonyms: BCAS2; DAM1; Pre-mRNA-splicing factor SPF27; Breast carcinoma-amplified sequence 2; DNA amplified in mammary carcinoma 1 protein; Spliceosome-associated protein SPF 27

GeneID: Human: 10286; Mouse: 68183

Research Use Only